Recent Updates
Recently added Catalysts
NTHI Positive Sentiment

Revolutionizing The Fight Against Cancer

Key Takeaway: Dr. Thomas Chen, CEO of NeOnc Technologies, is pioneering a novel platform technology aimed at delivering therapeutics directly to the brain, potentially improving treatment efficacy for brain cancer and CNS disorders. His extensive qualifications and experience in neurosurgery and research bolster the company's mission to revolutionize cancer treatment. NeOnc's advancements may significantly impact patient outcomes in neuro-oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Innovative platform technology targeting brain cancer treatment.
  • Potential to overcome Blood-Brain Barrier limitations.
  • Expert leadership with Dr. Thomas Chen's extensive background.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Perillyl alcohol
Phase 1 · Glioblastoma Multiforme

Full Press Release Details

Dr. Thomas Chen, MD, Ph.D. is Founder, CEO & CSO, and Board Director, of NeOnc Technologies ( https://neonc.com/ ), a developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB), providing patients with potentially more effective treatments.
NeOnc is developing a portfolio of treatments for brain cancer and other central nervous system (CNS) disorders.
Dr. Chen is a board-certified neurosurgeon and the Director of Surgical Neuro-Oncology at USC where he is also a tenured Professor of Neurosurgery and Pathology ( https://keck.usc.edu/faculty-search/thomas-c-chen/ ).
Dr. Chen graduated summa cum laude from the University of Illinois at Urbana-Champaign, where he also received Bronze Tablet honors and was inducted into the Phi Beta Kappa national academic honor society. He attended the University of California, San Francisco, where he obtained his MD, and was inducted into the Alpha Omega Alpha National Medical Honor Society. He underwent neurosurgery training at USC and obtained a Ph.D. degree in pathobiology where his thesis was on the role of immunotherapy in malignant brain tumors.
Dr. Chen is also a fellowship-trained spine surgeon and one of a few surgical neuro-oncologists in the country specializing in spine cancer surgery. He maintains a busy clinical practice in both surgical neuro-oncology and spine surgery and heads a research laboratory focused on glioma biology.
Dr. Chen has published extensively on glioma biology and neurosurgery. He is on the editorial board for The Spine Journal and on the review board for Neurosurgery and Journal of Neurosurgery. He also serves on numerous national neurosurgery committees.
#NeOnc #ThomasChen #NeurologicalSurgery #Neurosurgery #BrainTumor #Glioblastoma #Glioma #BloodBrainBarrier #NeuroOncology #Temozolomide #PerillylAlcohol #Meningioma #Neurology #CNS #SpinalCordInjury #BrainMetastases #Alzheimers #ParkinsonsDisease #Neuropathology #MedicalOncology #Chemotherapy #RadiationOncology #USC #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #Research
Support the show

Frequently Asked Questions

What is NeOnc Technologies focused on?

NeOnc Technologies is developing treatments for brain cancer and CNS disorders.

Who is Dr. Thomas Chen?

Dr. Thomas Chen is the Founder, CEO, and CSO of NeOnc Technologies.

What is the significance of the Blood-Brain Barrier?

The Blood-Brain Barrier restricts drug delivery to the brain, impacting treatment efficacy.

What are Dr. Chen's qualifications?

Dr. Chen is a board-certified neurosurgeon with extensive experience in neuro-oncology.

Last updated: Feb 5, 2025